THW - abrdn World Healthcare Fund

What this means for you

No investor has reported owning 5% or more of this fund. That is the normal state for most closed-end funds.

Nothing is required of you. If that changes, the notice appears here within a day of being filed with the regulator.

Email me if this changes

What happened, and when

1. May 15, 2026

   The fund said it may sell new shares.

   Original document →

2. Dec 5, 2025

   The fund said it may sell new shares.

   Original document →

About this fund

• Run by abrdn Inc. As of Sept 30, 2025, from the fund's yearly report. Original document →
• Size: about $566 million of holdings, as of June 30, 2026. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Borrowing: the fund borrows about 18% on top of its own money, as of June 30, 2026. Borrowed money makes gains and losses bigger. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Costs: 1.3% a year in management fees; 3% a year in total, including interest on borrowed money. Fiscal year ended Sept 30, 2025. As of Sept 30, 2025, from the fund's yearly report. Original document →
• Payouts: last fiscal year (ended Sept 30, 2025) the fund paid $1.40 a share. $0.81 of that was income; $0.59 was your own money back, not income. As of Sept 30, 2025, from the fund's annual report. Original document →
• Value of holdings per share at the last fiscal year end (Sept 30, 2025): $12.71. The shares traded at $12.60, about 0.9% below that. As of Sept 30, 2025, from the fund's yearly report. Original document →
  Over the last two years the gap ranged from 9.4% below to 6.1% above. As of March 31, 2026, from the fund's annual report. Original document →
• How the holdings did: up 18% over the last three months we have (April-June 2026), before the share price is taken into account. Over the last 12 months: +46.1%. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• How the holdings did over the fiscal year (ended Sept 30, 2025): the value of the holdings returned +12.5%. How the share price did: the shares returned +7.3% over the same year, counting payouts and the change in the market price. As of Sept 30, 2025, from the fund's annual report. Original document →
• First reported to the regulator in 2015.

What the fund holds

Mostly shares (84%), the rest bonds, preferred shares and derivatives. About 54% issued in the U.S.

The fund also sells options on its holdings to raise income.

1. uniQure NV - 6.4%
2. AstraZeneca PLC - 4.9%
3. VeraDermics - 4.2%
4. Abivax SA - 4%
5. Derivatives - 3.6%
6. Sanofi SA - 3.5%
7. Veradermics, Inc. - 3.2%
8. Argenx SE - 3.2%
9. Novo Nordisk A/S - 3.1%
10. Abbott Laboratories - 2.9%

As of June 30, 2026, from the fund's quarterly holdings report. Original document →